Le Lézard
Classified in: Health, Science and technology
Subjects: NPT, PER

AlloSource Announces Raime Leeby Muhle As Chief Financial Officer


CENTENNIAL, Colo., Dec. 14, 2017 /PRNewswire-USNewswire/ -- AlloSource, one of the nation's largest providers of cartilage, bone, skin, soft-tissue and cellular allografts for use in surgical procedures and wound care to advance patient healing, today announced the appointment of Raime Leeby Muhle as Chief Financial Officer.

With over 18 years of experience, her background spans from emerging high growth businesses to large and mature organizations. She has worked in a variety of industries including technology, distribution, manufacturing, and telecommunications. Leeby Muhle's expertise in complex environments, as well as working cross-functionally, will help her lead the accounting, financial, and information technology teams at AlloSource. Leeby Muhle is taking over for current Chief Financial Officer, Olivia Thompson, who is transitioning into retirement to focus on project-based work.

"We are thrilled to welcome Raime to our executive team," said Thomas Cycyota, AlloSource President and Chief Executive Officer. "Her financial expertise and leadership, as well as her passion for our mission, will help drive AlloSource's growth as we continue to evolve the advanced allograft therapies we provide for surgeons."

Leeby Muhle has held various senior-level roles with finance and operational responsibilities. Prior to AlloSource, she served in key leadership positions at Arrow Electronics and Level 3 Communications.

"AlloSource has such a unique impact on our communities, and I am committed to helping the company continue to grow and innovate," said Leeby Muhle. "I look forward to putting my background and skills towards our goal of achieving greater results in advancing biological healing."

About AlloSource
AlloSource is one of the largest nonprofit cellular and tissue networks in the country, offering more than 200 types of precise cartilage, cellular, bone, skin and soft-tissue allografts to advance patient healing. For more than 20 years, AlloSource's products have bridged the proven science of allografts with the advanced technology of cells, offering life-saving and life-enhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma and wound care procedures. As the world's largest processor of cellular bone allografts, fresh cartilage tissue for joint repair and skin allografts to help patients heal from severe burns, AlloSource delivers unparalleled expertise and service to its growing network of surgeons, partners, and the country's most reputable organ procurement organizations. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org.

Media Contact
Megan Duggan
AlloSource
720. 382. 2766
[email protected]

SOURCE AlloSource


These press releases may also interest you

at 08:25
NOVA LEAP HEALTH CORP. ("Nova Leap" or "the Company"), a growing home health care organization, is pleased to announce that it has executed a definitive agreement (the "Agreement"), dated April 25, 2024, to acquire a home care services company ("the...

at 08:20
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory...

at 08:19
Nitto Denko Avecia Inc. and Nitto Denko Avecia Pharma Services (Nitto Avecia), a global leader in contract development and manufacturing of oligonucleotides for the therapeutic market announced today that Tammy Cooper will be appointed President of...

at 08:05
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...

at 08:05
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage...

at 08:02
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative...



News published on and distributed by: